668 related articles for article (PubMed ID: 26306400)
21. Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia.
De Nunzio C; Salonia A; Gacci M; Ficarra V
World J Urol; 2020 Nov; 38(11):2771-2779. PubMed ID: 32060633
[TBL] [Abstract][Full Text] [Related]
22. Serenoa repens for benign prostatic hyperplasia.
Wilt T; Ishani A; Mac Donald R
Cochrane Database Syst Rev; 2002; (3):CD001423. PubMed ID: 12137626
[TBL] [Abstract][Full Text] [Related]
23. Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia.
Russo A; Capogrosso P; La Croce G; Ventimiglia E; Boeri L; Briganti A; Damiano R; Montorsi F; Salonia A
Expert Opin Drug Saf; 2016 Dec; 15(12):1661-1670. PubMed ID: 27232207
[TBL] [Abstract][Full Text] [Related]
24. Serenoa repens for benign prostatic hyperplasia.
Tacklind J; MacDonald R; Rutks I; Wilt TJ
Cochrane Database Syst Rev; 2009 Apr; (2):CD001423. PubMed ID: 19370565
[TBL] [Abstract][Full Text] [Related]
25. The effect of hexanic extract of Serenoa repens on prostatic inflammation: results from a randomized biopsy study.
Gravas S; Samarinas M; Zacharouli K; Karatzas A; Tzortzis V; Koukoulis G; Melekos M
World J Urol; 2019 Mar; 37(3):539-544. PubMed ID: 30027406
[TBL] [Abstract][Full Text] [Related]
26. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia.
Boyle P; Robertson C; Lowe F; Roehrborn C
BJU Int; 2004 Apr; 93(6):751-6. PubMed ID: 15049985
[TBL] [Abstract][Full Text] [Related]
27. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia.
Plosker GL; Brogden RN
Drugs Aging; 1996 Nov; 9(5):379-95. PubMed ID: 8922564
[TBL] [Abstract][Full Text] [Related]
28. Serenoa repens for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Current Evidence and Its Clinical Implications in Naturopathic Medicine.
Ooi SL; Pak SC
J Altern Complement Med; 2017 Aug; 23(8):599-606. PubMed ID: 28436684
[TBL] [Abstract][Full Text] [Related]
29. Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study.
Oelke M; Giuliano F; Baygani SK; Melby T; Sontag A
BJU Int; 2014 Oct; 114(4):568-75. PubMed ID: 24612148
[TBL] [Abstract][Full Text] [Related]
30. Anti-inflammatory properties of Lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia.
Bernichtein S; Pigat N; Camparo P; Latil A; Viltard M; Friedlander G; Goffin V
Prostate; 2015 May; 75(7):706-22. PubMed ID: 25683150
[TBL] [Abstract][Full Text] [Related]
31. [Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial].
Glemain P; Coulange C; Billebaud T; Gattegno B; Muszynski R; Loeb G;
Prog Urol; 2002 Jun; 12(3):395-403; discussion 404. PubMed ID: 12189745
[TBL] [Abstract][Full Text] [Related]
32. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial).
Morgia G; Russo GI; Voce S; Palmieri F; Gentile M; Giannantoni A; Blefari F; Carini M; Minervini A; Ginepri A; Salvia G; Vespasiani G; Santelli G; Cimino S; Allegro R; Collura Z; Fragalà E; Arnone S; Pareo RM
Prostate; 2014 Nov; 74(15):1471-80. PubMed ID: 25154739
[TBL] [Abstract][Full Text] [Related]
33. Multicentre study on the efficacy and tolerability of an extract of Serenoa repens in patients with chronic benign prostate conditions associated with inflammation.
Giulianelli R; Pecoraro S; Sepe G; Leonardi R; Gentile BC; Albanesi L; Brunori S; Mavilla L; Pisanti F; Giannella R; Morello P; Tuzzolo D; Coscione M; Galasso F; D'Angelo T; Ferravante P; Morelli E; Miragliuolo A;
Arch Ital Urol Androl; 2012 Jun; 84(2):94-8. PubMed ID: 22908779
[TBL] [Abstract][Full Text] [Related]
34. Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?
Argirović A; Argirović D
Vojnosanit Pregl; 2013 Dec; 70(12):1091-6. PubMed ID: 24450252
[TBL] [Abstract][Full Text] [Related]
35. An improvement in sexual function is related to better quality of life, regardless of urinary function improvement: results from the IDIProst® Gold Study.
Cai T; Morgia G; Carrieri G; Terrone C; Imbimbo C; Verze P; Mirone V;
Arch Ital Urol Androl; 2013 Dec; 85(4):184-9. PubMed ID: 24399119
[TBL] [Abstract][Full Text] [Related]
36. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay.
Vela Navarrete R; Garcia Cardoso JV; Barat A; Manzarbeitia F; López Farré A
Eur Urol; 2003 Nov; 44(5):549-55. PubMed ID: 14572753
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and tolerability of the lipidosterolic extract of Serenoa repens (Permixon) in benign prostatic hyperplasia: a double-blind comparison of two dosage regimens.
Stepanov VN; Siniakova LA; Sarrazin B; Raynaud JP
Adv Ther; 1999; 16(5):231-41. PubMed ID: 10915398
[TBL] [Abstract][Full Text] [Related]
38. The Role of Combination Therapy with α-Blockers and Hexanic Extract of
De Nunzio C; Salonia A; Gacci M; Ficarra V
J Clin Med; 2022 Dec; 11(23):. PubMed ID: 36498751
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of the Hexanic Extract of
Alcaraz A; Gacci M; Ficarra V; Medina-Polo J; Salonia A; Fernández-Gómez JM; Ciudin A; Castro-Díaz D; Rodríguez-Antolín A; Carballido-Rodríguez J; Cózar-Olmo JM; Búcar-Terrades S; Pérez-León N; Brenes-Bermúdez FJ; Molero-García JM; Ledesma AF; Herdman M; Manasanch J; Angulo JC; Group OBOTQS
J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207238
[TBL] [Abstract][Full Text] [Related]
40. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Gacci M; Vittori G; Tosi N; Siena G; Rossetti MA; Lapini A; Vignozzi L; Serni S; Maggi M; Carini M
J Sex Med; 2012 Jun; 9(6):1624-33. PubMed ID: 22510238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
